128 related articles for article (PubMed ID: 20649056)
1. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
[TBL] [Abstract][Full Text] [Related]
4. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
Zelenitsky SA; Ariano RE
J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
Washington CB; Hou SY; Campanella C; Hughes N; Brown S; Berner B
J Clin Pharmacol; 2005 Nov; 45(11):1236-44. PubMed ID: 16239356
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
8. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats.
Albarellos GA; Kreil VE; Landoni MF
J Vet Pharmacol Ther; 2004 Jun; 27(3):155-62. PubMed ID: 15189301
[TBL] [Abstract][Full Text] [Related]
11. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
[TBL] [Abstract][Full Text] [Related]
12. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
Czock D; Rasche FM
Eur J Med Res; 2005 Apr; 10(4):145-8. PubMed ID: 15946909
[TBL] [Abstract][Full Text] [Related]
13. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
Conte JE; Golden JA; McIver M; Zurlinden E
Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and in vitro activity of the ciprofloxacin-azlocillin combination (ratio 1:10) against gram-negative bacteria from non-neutropenic haematologic patients.
Piccolomini R; Di Girolamo A; Iacone A; Fioritoni G; Cellini L; Nicoletti M; D'Antonio D
Drugs Exp Clin Res; 1991; 17(9):455-60. PubMed ID: 1822439
[TBL] [Abstract][Full Text] [Related]
15. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
Lipman J; Gous AG; Mathivha LR; Tshukutsoane S; Scribante J; Hon H; Pinder M; Riera-Fanego JF; Verhoef L; Stass H
Intensive Care Med; 2002 Apr; 28(4):493-500. PubMed ID: 11967606
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery.
Yu-Speight AW; Kern TJ; Erb HN
Vet Ophthalmol; 2005; 8(3):181-7. PubMed ID: 15910371
[TBL] [Abstract][Full Text] [Related]
19. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
20. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
